Cipla gets 6 USFDA observations for Maha facility
Mumbai: Cipla has received six inspectional observations in Form 483 from the United States Food and Drug Administration (USFDA) at the conclusion of a routine current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility of the Company located in Patalganga, Maharashtra, India. The inspection was held from 28th March 2024 to 4th April 2024. “The Company […]